Key result
Captopril significantly reduced circulating ET-1 concentrations (P<.03) and increased total glucose uptake (P<.03) in lean normotensive men with non-insulin-dependent diabetes mellitus.
Why the study?
Does captopril reduce plasma endothelin-1 levels and improve insulin sensitivity in lean normotensive men with NIDDM?
Population
15 lean normotensive men with non-insulin-dependent diabetes mellitus (NIDDM), mean age 51.6 ± 3.8 years.
Comparison
Captopril 25 mg twice daily for 1 week vs Placebo
Design
RCT, randomized fashion, double-blind
Follow-up
1 week
Authors
Loading...
Captopril may reduce ET-1 in NIDDM; extends ACEI vascular effects beyond BP lowering in diabetes.
RCT (n=15)
double-blind
randomized
Does captopril reduce plasma endothelin-1 levels and improve insulin sensitivity in lean normotensive men with NIDDM?
p-value: p=<.03
Short-term captopril therapy reduces circulating endothelin-1 levels and improves insulin sensitivity in lean normotensive men with type 2 diabetes.
Ferri et al. (1995) conducted an RCT in non-insulin-dependent diabetes mellitus (NIDDM) (n=15). captopril vs. placebo was evaluated on plasma endothelin-1 (ET-1) levels and total glucose uptake (p=<.03). Captopril significantly reduced circulating ET-1 concentrations (P<.03) and increased total glucose uptake (P<.03) in lean normotensive men with non-insulin-dependent diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: